InvestSMART

Ceryvyn Therapeutics Limited (ASX:CYV)

ALERT: Price-sensitive ASX Announcement for CYV
Current share price for CYV : $0.011 -0.001 (-8.33%)+
Announcement
Release
27 Jul 2026 9:55AM
Price at Release
$0.012
Full Release
download
Summary
Ceryvyn Therapeutics Limited released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the period ending 30 June 2026. The company, formerly known as Opthea Limited, has made significant progress in its lymphangioleiomyomatosis (LAM) program with the advancement of CYV-101, a first-in-class fusion protein therapy. During this quarter, trading in securities was reinstated on the ASX, and the company established a Scientific Advisory Board to guide its LAM program. Financially, the company held AUD $30 million in cash and equivalents, with a net cash outflow from operations of AUD $1.1 million. The company's strategic focus on LAM reflects its commitment to addressing unmet medical needs with innovative therapies.
Key Points
  • Reinstatement of trading in securities on the ASX on 3 June 2026.
  • Establishment of a Scientific Advisory Board to support the LAM program.
  • Renaming of the company to Ceryvyn Therapeutics Limited.
  • Progression in LAM development program with CYV-101 nebulisation studies.
  • Cash balance at the end of the period was AUD $30 million.
  • Net cash outflow from operations was AUD $1.1 million.
  • Focus on developing a treatment for lymphangioleiomyomatosis (LAM).
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.